Toward the end of epidemics
We’re working to stop meningitis in Africa
In response to the largest meningitis epidemic in African history, PATH began working in partnership with the World Health Organization on the Meningitis Vaccine Project (MVP) to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines.
Our progress so far
Working with the Serum Institute of India Ltd. and partners across the world, MVP developed an effective, affordable vaccine that targets the pathogen that causes most epidemics in sub-Saharan Africa: group A Neisseria meningitidis. The vaccine, called MenAfriVac®, was developed in less than ten years and at one-tenth the cost of a typical vaccine.
Introduction of MenAfriVac® through immunization campaigns began in December 2010. Since then, mass immunization campaigns in 15 countries have reached more than 217 million people since the vaccine was launched in 2010, with 63 million vaccinated in 2014 alone. With this highly effective vaccine, the recurring epidemics–affecting thousands of infants, children, and young people–have been eliminated.
While the MVP project has met its objectives and wrapped up, the work goes on. PATH is working with in-country and global partners to ensure the use of MenAfriVac® is implemented into standard childhood immunization programs and to ensure that the long-term control of Meningitis A epidemics in the meningitis belt is sustained.
MenAfriVac is a registered trademark of Serum Institute of India Ltd.
Banner photo: PATH.